BACKGROUND: Discernible improvements have taken place in soft tissue sarcoma patient survivorship and quality of life over the past 20 years, with overall 5-year survival currently at approximately 50%. Shifts in treatment have taken place over the past decade, from single-modality treatment involving radical surgery to sophisticated limb-salvage strategies combined with radiation therapy and protocol-administered chemotherapy. METHODS: To identify patterns of treatment and outcome, all soft tissue sarcoma cases diagnosed in 1988 and 1993 as recorded in the National Cancer Data Base were analyzed on the basis of histology and anatomic site. RESULTS: There was an increase in sarcomas originating in the pleura with a concurrent increase in mesotheliomas. A shift toward more advanced disease was also noted. Limb-sparing surgical procedures are now standard. However, it appears from stage subset analysis that many Stage II and III patients are undertreated due to lack of multimodality therapy usage. CONCLUSIONS: Use of pretreatment multimodality planning conferences will increase the likelihood that stage-appropriate combinations of surgery, radiation therapy, and chemotherapy will be used. In turn, election of multimodality approaches should increase the possibility of improved overall and disease free survival in the future.
BACKGROUND: Discernible improvements have taken place in soft tissue sarcomapatient survivorship and quality of life over the past 20 years, with overall 5-year survival currently at approximately 50%. Shifts in treatment have taken place over the past decade, from single-modality treatment involving radical surgery to sophisticated limb-salvage strategies combined with radiation therapy and protocol-administered chemotherapy. METHODS: To identify patterns of treatment and outcome, all soft tissue sarcoma cases diagnosed in 1988 and 1993 as recorded in the National Cancer Data Base were analyzed on the basis of histology and anatomic site. RESULTS: There was an increase in sarcomas originating in the pleura with a concurrent increase in mesotheliomas. A shift toward more advanced disease was also noted. Limb-sparing surgical procedures are now standard. However, it appears from stage subset analysis that many Stage II and III patients are undertreated due to lack of multimodality therapy usage. CONCLUSIONS: Use of pretreatment multimodality planning conferences will increase the likelihood that stage-appropriate combinations of surgery, radiation therapy, and chemotherapy will be used. In turn, election of multimodality approaches should increase the possibility of improved overall and disease free survival in the future.
Authors: Nicola Tamburini; Francesco Quarantotto; Pio Maniscalco; Elena Garelli; William Grossi; Gabriele Anania; Giorgio Narciso Cavallesco Journal: J Thorac Dis Date: 2014-09 Impact factor: 2.895
Authors: Eelco de Bree; Alexander Karatzanis; Jennifer L Hunt; Primož Strojan; Alessandra Rinaldo; Robert P Takes; Alfio Ferlito; Remco de Bree Journal: Eur Arch Otorhinolaryngol Date: 2014-05-07 Impact factor: 2.503
Authors: Jose Duran-Moreno; Katerina Kampoli; Emmanouil I Kapetanakis; Maria Mademli; Nektarios Koufopoulos; Periklis G Foukas; Kostas Kostopanagiotou; Periklis Tomos; Anna Koumarianou Journal: In Vivo Date: 2019 Sep-Oct Impact factor: 2.155
Authors: Shirish M Gadgeel; Linda C Harlan; Christopher A Zeruto; Michael Osswald; Ann G Schwartz Journal: Cancer Date: 2009-06-15 Impact factor: 6.860
Authors: Swetlana Rot; Helge Taubert; Matthias Bache; Thomas Greither; Peter Würl; Alexander W Eckert; Johannes Schubert; Dirk Vordermark; Matthias Kappler Journal: BMC Cancer Date: 2011-10-06 Impact factor: 4.430